## Contents

### Program Faculty

[Page i]

### Sponsorship and CME Credit

[Page ii]

### CME Activity Assessment and Evaluation

[Page iii]

### Advances in Treating Metastatic Bone Cancer: Summary Statement for the First Cambridge Conference


[Page 6209s]

### Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases

Theresa A. Guise, Khalid S. Mohammad, Gregory Clines, Elizabeth G. Stebbins, Darren H. Wong, Linda S. Higgins, Robert Vessella, Eva Corey, Susan Padalecki, Larry Suva, and John M. Chirgwin

[Page 6213s]

### Genomics and Proteomics of Bone Cancer

Aaron G. Marguiles, V. Suzanne Klimberg, Sudeepa Bhattacharrya, Dana Gaddy, and Larry J. Suva

[Page 6217s]

### Molecular Mechanisms of Action of Bisphosphonates: Current Status

Anke J. Roelofs, Keith Thompson, Sharon Gordon, and Michael J. Rogers

[Page 6222s]

### Biology of Bone Cancer Pain

Michael J. Goblirsch, Pawel P. Zwolak, and Denis R. Clohisy

[Page 6231s]

### The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient’s Experience

Charles S. Cleeland

[Page 6236s]

### Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity

Robert E. Coleman

[Page 6243s]

### High-Line Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

Oyvind S. Bruland, Sten Nilsson, Darrell R. Fisher, and Roy H. Larsen

[Page 6250s]

### Breast Cancer: Bisphosphonate Therapy for Metastatic Bone Disease

Jean-Jacques Body

[Page 6258s]

### Multistate Analysis of Skeletal Events in Patients with Bone Metastases

Richard J. Cook and Pierre Major

[Page 6264s]

### New Potential Targets for Treating Myeloma Bone Disease

G. David Roodman

[Page 6270s]

### Wnt Antagonism in Multiple Myeloma: A Potential Cause of Uncoupled Bone Remodeling

Roger N. Pearse

[Page 6274s]

### Treatment for Myeloma Bone Disease

Howard S. Yeh and James R. Berenson

[Page 6279s]

### Targeting Factors Involved in Bone Remodeling as Treatment Strategies in Prostate Cancer

Robert L. Vessella and Eva Corey

[Page 6285s]

### Src Inhibitors in Metastatic Bone Disease

Brendan F. Boyce, Lianping Xing, Zhengqiang Yao, Teruhito Yamashita, William C. Shakespeare, Yihan Wang, Chester A. Metcalf III, Raji Sundaramoorthi, David C. Dalgarno, John D. Iuliucci, and Tomi K. Sawyer

[Page 6291s]

### Targeting Bone Metastasis in Prostate Cancer with Endothelin Receptor Antagonists

Michael A. Carducci and Antonio Jimeno

[Page 6296s]

### Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer

Trevor Powles, Eugene McGrooksey, and Alexander Paterson

[Page 6301s]

### Future Treatment of Bone Metastases

Allan Lipton

[Page 6305s]

### Skeletal Complications of Breast Cancer Therapies

Angela Hirbe, Elizabeth A. Morgan, Özge Uluc̣kan, and Katherine Weilbaecher

[Page 6309s]

### Treatment-Related Osteoporosis in Men with Prostate Cancer

Matthew R. Smith

[Page 6315s]